Determination Of Lornoxicam Research Articles

Determination of lornoxicam by UV spectroscopic method in bulk and combined dosage form

Objective: In the present study a suitable UV Spectroscopic method was developed and validated for Lornoxicam determination in bulk and combined dosage form. Methods: UV Spectrophotometric method was performed at 376nm and samples were prepared with a solution of 0.1N HCl, validation parameters like accuracy, precision, LOD, LOQ, recovery study and range were determined. Results: The linearity demonstrated a correlation coefficient of 0.9992 various validation parameters like accuracy, precision, LOD, LOQ, recovery study and range were found to be within the specified range. Conclusion: The proposed method was simple, rapid, precise, accurate and sensitive and can be used for routine analysis of Lornoxicam in bulk and combined dosage form.

Simultaneous Derivative Spectrophotometric Determination of Lornoxicam and Paracetamolin Tablet Dosage Forms

Lornoxicam and Paracetamol in combined dosage forms (Tablets). The zero crossing point of Paracetamol (247.42 nm) has been selected for the quantification of Lornoxicam whereas the zero crossing point of Lornoxicam (233.28 nm) has been selected for the quantification of Paracetamol from the first order derivative spectrum observed in borate buffer. The method obeys Beer-Lambert’s law over the concentration range 5-50 µg/ml for Lornoxicam and 5-60 µg/ml for Paracetamol. The proposed method was validated and can be used for the analysis of tablet dosage forms containing Lornoxicam and Paracetamol. K ey words: Lornoxicam, Paracetamol, Spectrophotometry, Derivative spectroscopy, Validation.

Characterization and application of lornoxicam, europium(III), and lysozyme fluorescence

ABSTRACTA novel and sensitive spectrofluorimetric method was developed for the determination of lornoxicam. The method was based on the fluorescence enhancement of europium(III) by formation of a ternary complex with lornoxicam in the presence of lysozyme as the co-ligand. The fluorescence signal for the lornoxicam-europium (III)-lysozyme system was monitored at an excitation wavelength of 620 nm and an emission wavelength of 390 nm. The parameters affecting the fluorescence intensity were optimized systematically and under these conditions the signal was directly proportional to the concentration of lornoxicam from 9.0 × 10−5 to 1.0 × 10−2 µg · mL−1. The detection limit was 2.7 × 10−5 µg · mL−1. The relative standard deviation for thirteen replicate measurements of 1.0 × 10−3 µg · mL−1 lornoxicam was 1.8%. This method was employed for the determination of lornoxicam in pharmaceutical formulations and biological fluids. The mechanism of fluorescence for the lornoxicam-europium(III)-lysozyme system was discussed.

Applications of Carbon Based Electrodes for Voltammetric Determination of Lornoxicam in Pharmaceutical Dosage Form and Human Serum

A simple, reliable and selective differential pulse (DP) and square wave (SW) voltammetric methods at glassy carbon (GC) and boron-doped diamond (BDD) electrodes of lornoxicam in pharmaceutical dosage form and in spiked human serum samples have been developed and evaluated. The possible oxidation mechanism was discussed. The voltammetric study of the model compounds allowed elucidating the possible oxidation mechanism of lornoxicam. The dependence of the peak current and peak potentials on pH, concentration, nature of the buffer, and scan rate were investigated. The oxidation of lornoxicam gave a single and irreversible peak at both electrodes. The process was found diffusion controlled. For glassy carbon electrode, the linearity of the calibration curve was obtained in range of 4x10-7 M to 2x10-5 M for DPV method and 4x10-7 M to 4x10-5 M for SWV method in 0,1 M sulphuric acid solutions. Using boron-doped diamond electrode, the plot of the calibration curve was linear between 6x10-7 M and 1x10-4 M for both voltammetric methods in pH 2 BR buffer. The repeatability, reproducibility, precision and accuracy of the proposed methods were investigated.

Liquid chromatography-electrospray lonization tandem mass spectrometric determination of lornoxicam in human plasma

A rapid, sensitive and selective liquid chromatography-electrospray ionization tandem mass spectrometric (LC-ESI-MS/MS) method for the determination of lornoxicam in human plasma was developed. Lornoxicam and isoxicam (internal standard) were extracted from human plasma with ethyl acetate at acidic pH and analyzed on a Sunfire C18 column with the mobile phase of methanol:ammonium formate (10 mM, pH 3.0) (70:30, v/v). The analyte was detected using a mass spectrometer, equipped with electrospray ion source. The instrument was set in the multiple-reaction-monitoring mode. The standard curve was linear (r = 0.9998) over the concentration range of 0.50-500 ng/mL. The coefficient of variation and relative error for intra- and inter-assay at four QC levels were 0.7 to 4.2% and -4.5 to 5.0%, respectively. The recoveries of lornoxicam and isoxicam were 87.8% and 66.5%, respectively. The lower limit of quantification for lornoxicam was 0.50 ng/mL using a 200 pL plasma sample. This method was successfully applied to a pharmacokinetic study of lornoxicam after oral administration of lornoxicam (8 mg) to humans.